Tarsus Pharmaceuticals advertising spend, FY2025

Tarsus Pharmaceuticals (TARS) reported $121M of advertising expense for the fiscal year ended Dec 31, 2025. That is 26.9% of revenue of $451M. Up 306.7% from FY2024.

Ad spend, FY2025
$121M
year ended Dec 31, 2025
Change vs prior year
+306.7%
vs FY2024
Share of revenue
26.9%
of $451M revenue
Rank by ad spend
#309
of 458 companies

Key facts

  • Ad spend is 13x its FY2023 level ($9.4M), slower than revenue (26x).
  • FY2025 is the highest year on file, going back to FY2022.
  • Ad spend has risen 2 years in a row.
  • Tarsus Pharmaceuticals spends more on advertising than 33% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is 5.9x the median of 4.5%.

Ad spend by fiscal year

$0 $50M $100M $150M FY2022 (ended 2022-12-31): $0 2022 FY2023 (ended 2023-12-31): $9.4M 2023 FY2024 (ended 2024-12-31): $29.8M 2024 FY2025 (ended 2025-12-31): $121M 2025 $121M

Ad spend as % of revenue

0% 20% 40% 60% FY2022 (ended 2022-12-31): 0.0% 2022 FY2023 (ended 2023-12-31): 53.9% 2023 FY2024 (ended 2024-12-31): 16.3% 2024 FY2025 (ended 2025-12-31): 26.9% 2025 26.9%

Ad spend in context, FY2025

Advertising was 28.4% of selling, general and administrative expense. Advertising was 1.9x research and development spending. The company reported an operating loss of $71M.

Advertising $121M AdvertisingExpense
Selling, general and administrative $427M ad spend = 28.4%
Research and development $64.3M ad spend = 1.9x R&D
Operating loss -$71M
Net loss -$66.4M

Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.

History

Download CSV
Fiscal year Period end Ad spend YoY Revenue Ad / revenue Tag Filing
FY2025 Dec 31, 2025 $121M +306.7% $451M 26.9% AdvertisingExpense 10-K Feb 23, 2026
FY2024 Dec 31, 2024 $29.8M +217.0% $183M 16.3% AdvertisingExpense 10-K Feb 23, 2026
FY2023 Dec 31, 2023 $9.4M n/a $17.4M 53.9% AdvertisingExpense 10-K Feb 23, 2026
FY2022 Dec 31, 2022 $0 n/a $25.8M 0.0% AdvertisingExpense 10-K Feb 25, 2025

Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank. A $0 value is what the filing tagged for that year.

What the figure is

Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).

Compared with similar spenders

The 6 companies closest to Tarsus Pharmaceuticals in latest-year ad spend.

Rank Company Ad spend Ad / revenue YoY Fiscal year
305 Generac $123M 2.9% +5.7% FY2025
306 Lyft $123M 1.9% -10.2% FY2025
307 Snowflake $122M 2.6% +16.3% FY2026
308 Insulet $121M 4.5% +43.9% FY2025
309 Tarsus Pharmaceuticals $121M 26.9% +306.7% FY2025
310 Ziff Davis $119M 8.2% +4.0% FY2025
311 Cisco Systems $119M 0.2% -36.0% FY2026

Full ranking of 458 companies · Biggest increases #3 · Highest ad-to-revenue #25 · New $50M spenders #1 · More on ads than R&D #65 · Ads above operating profit #108

Questions

How much does Tarsus Pharmaceuticals spend on advertising?

Tarsus Pharmaceuticals spent $121M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 23, 2026.

What percentage of revenue does Tarsus Pharmaceuticals spend on advertising?

26.9% of revenue in fiscal 2025 ($121M against $451M). The median across the 458 companies tracked is 4.5%.

Is Tarsus Pharmaceuticals spending more on advertising?

Yes. Ad spend rose 306.7% in fiscal 2025 from fiscal 2024. It has risen 2 years in a row.

How does Tarsus Pharmaceuticals rank by advertising spend?

#309 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.

Does Tarsus Pharmaceuticals spend more on advertising than on R&D?

Yes. In fiscal 2025 it spent $121M on advertising and $64.3M on research and development.

What does Tarsus Pharmaceuticals's advertising figure include?

Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).

Company and source

Filing
10-K for FY2025, filed Feb 23, 2026
Accession number
0001819790-26-000019
Company
Tarsus Pharmaceuticals, Inc., CIK 1819790, SIC 2836 (Biological Products, (No Diagnostic Substances))
Headquarters
Irvine, CA
Incorporated in
DE
Fiscal year ends
December 31
Listed on
Nasdaq
SEC filer status
Large accelerated filer
Data
SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
Cite
Tarsus Pharmaceuticals advertising spend, FY2022-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 23, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/tarsus-pharmaceuticals/advertising-spend/
Download
CSV, all years · CSV, all 458 companies